Logo

BON

Bon Natural Life Limited

BON

Bon Natural Life Limited • NASDAQ
$1.85 ▼ -1.60% (-0.03)
Market Cap $11.26 M
52w High $73.75
52w Low $1.14
Dividend Yield 0%
P/E 0.09
Volume 11.43K
Outstanding Shares 6.09M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $7.95M ▼ $1.624M ▼ $169.227K ▼ 2.129% ▼ $0.56 ▲ $1.203M ▼
Q4-2024 $13.661M ▲ $2.353M ▼ $408.691K ▲ 2.992% ▲ $0.23 ▲ $1.302M ▲
Q2-2024 $10.184M ▼ $2.884M ▲ $-10.52K ▼ -0.103% ▼ $-0.008 ▼ $770.544K ▼
Q4-2023 $15.372M ▲ $1.189M ▼ $2.476M ▲ 16.108% ▲ $2.64 ▲ $3.605M ▲
Q2-2023 $14.15M $1.732M $2.12M 14.981% $2.38 $3.188M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $8.894M ▲ $71.584M ▲ $17.679M ▲ $53.522M ▲
Q4-2024 $80.466K ▼ $61.765M ▲ $17.416M ▲ $43.907M ▲
Q2-2024 $717.879K ▲ $50.08M ▲ $12.762M ▲ $36.694M ▲
Q4-2023 $112.816K ▼ $46.556M ▼ $10.574M ▼ $35.485M ▲
Q2-2023 $542.272K $47.207M $11.705M $34.988M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $169.227K ▼ $-4.296M ▲ $4.395K ▲ $12.322M ▲ $8.237M ▲ $-4.296M ▲
Q4-2024 $428.203K ▲ $-5.839M ▼ $-15.034K ▼ $6.243M ▲ $-60.674K ▼ $-5.845M ▼
Q2-2024 $-10.52K ▼ $-1.884M ▼ $-694 ▲ $2.512M ▲ $605.128K ▲ $-1.885M ▼
Q4-2023 $2.476M ▲ $1.526M ▲ $-1.168M ▼ $-759.668K ▼ $-429.521K ▼ $1.022M ▲
Q2-2023 $2.12M $-2.178M $-18.101K $1.915M $-298.589K $-2.196M

Five-Year Company Overview

Income Statement

Income Statement Revenue has stayed very small and fairly flat over the last few years, which suggests the business is not yet scaling meaningfully. Gross profit and operating results hover around break-even, with only modest profitability in one year and roughly no profit in the most recent periods. The very large swings in reported earnings per share are mostly the result of share count changes from reverse stock splits rather than big shifts in the underlying business. Overall, the income statement looks fragile: limited sales, thin margins, and little cushion if costs rise or growth plans take longer than expected.

Balance Sheet

Balance Sheet The balance sheet is compact, with a small asset base and only a modest equity cushion. Reported cash is minimal, which reduces financial flexibility and may increase reliance on timely collections or external funding. Debt levels appear low, which is a positive, but the combination of small scale and limited liquid resources means the company likely has less room to absorb setbacks than a larger, better-capitalized peer. In short, it’s a light, fairly simple balance sheet, but also a relatively thin safety net.

Cash Flow

Cash Flow Cash generation is weak. Operating cash flow recently turned slightly negative, and free cash flow follows the same pattern, as there is little capital spending to offset. That means the company is not yet self-funding its operations in a comfortable way and may need to depend on working capital shifts, new agreements, or outside capital to support growth. The lack of significant investment spending keeps cash needs from ballooning, but it also suggests that scaling up production or sales may require future funding if the business gains traction.

Competitive Edge

Competitive Edge Bon Natural Life occupies a narrow niche in natural, functional ingredients and health-related products. Its strengths come from specialized know-how in extraction technologies, an established patent portfolio, and participation in setting industry standards, all of which create some technical and regulatory barriers for rivals. The company also benefits from geographic proximity to key raw materials and from being one of the relatively few suppliers of certain ingredients like stachyose. However, overall scale is small, brand visibility is limited compared with major global packaged food and nutraceutical players, and the business appears highly dependent on a few product lines and partnerships. That leaves its competitive position promising but still relatively early-stage and exposed to execution and customer-concentration risks.

Innovation and R&D

Innovation and R&D Innovation is the clear highlight. The company has built proprietary extraction platforms for high-purity apple polyphenols and other bioactive ingredients, backed by multiple patents and contributions to national standards. It is moving from first- to second-generation products with higher bioactivity, which, if well received, can support premium positioning. The push into AI-driven compound discovery for weight management and microbiome-focused products adds a forward-looking, science-based angle that could open new markets and speed up development cycles. The key uncertainty is commercialization: translating this technology and research pipeline into consistent, sizable revenue in a crowded health and wellness field will require strong marketing, regulatory navigation, and reliable manufacturing and distribution partners.

Summary

Bon Natural Life is a very small, innovation-oriented company in the natural ingredients and health products space. Financially, it operates close to break-even with limited revenue, a thin equity buffer, almost no cash, and weak cash generation, which together point to a fragile financial profile. On the strategic side, it has meaningful technical strengths, a defensible niche in high-purity plant-based ingredients, and ambitious AI-driven R&D plans that could, in time, support faster growth and differentiation. The main story is one of contrast: a promising technology and product platform set against the realities of tiny scale, tight liquidity, and the need to successfully commercialize and scale partnerships to turn scientific potential into a durable, larger business.

NEWS

November 25, 2025 · 9:41 AM UTC

BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan

Read more

September 9, 2025 · 8:30 AM UTC

BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products

Read more

September 2, 2025 · 8:30 AM UTC

BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform

Read more